bBHC has applied and been registering 76 patents related to newly Elicited Pluripotent Stem cells without side effects in 146 countries and among these, 15 patents are registered in Korea.
bBHC welcomes collaborative research opportunities with global research centers and multinational pharmaceutical companies. Also, nEPS can be provided at your request any time for the purpose of research and development.
We participate many international biotechnology congresses to present our technology and please contact us to the below address for any inquiries.
∙ Company Name: bBHC co.,Ltd
∙ Established: 2012. 11. 01
∙ CEO: Mindy Minsun Oh
∙ Main business segments : stem cell research, cell therapy development, the cosmetics business
∙ Email: firstname.lastname@example.org